Phase 3 VALOR: Brepocitinib Delivers 15.3-Point TIS Gain, FDA Q3 2026 Review
In a global Phase 3 VALOR trial enrolling 241 dermatomyositis patients, brepocitinib 30 mg achieved a 15.3-point greater Total Improvement Score at week 52 versus placebo and doubled corticosteroid tapering rates. The FDA granted Priority Review to its NDA with a PDUFA action date in Q3 2026.
1. Trial Design and Primary Endpoint
The VALOR study randomized 241 adult dermatomyositis patients across 90 sites to brepocitinib 30 mg, brepocitinib 15 mg, or placebo. Brepocitinib 30 mg achieved a 15.3-point greater mean Total Improvement Score at week 52 versus placebo (P<0.001), meeting the primary endpoint.
2. Secondary Endpoints and Clinical Benefits
Brepocitinib 30 mg showed statistically significant and clinically meaningful improvements on all nine key secondary endpoints, including muscle strength, skin disease activity, physical function, and itch relief. Treatment effects appeared as early as week 4 and were sustained through week 52.
3. Corticosteroid Tapering and Safety
Nearly twice as many patients on brepocitinib 30 mg reduced background corticosteroids to ≤2.5 mg/day prednisone-equivalent compared to placebo. Serious infections were higher with brepocitinib but resolved with medical management, and adverse events leading to discontinuation were less frequent than placebo.
4. Regulatory Progress
The FDA has granted Priority Review to brepocitinib’s New Drug Application with a PDUFA target action date in the third quarter of 2026, positioning the therapy for potential approval and commercialization pending review outcomes.